scispace - formally typeset
W

William W. Busse

Researcher at University of Wisconsin-Madison

Publications -  740
Citations -  62685

William W. Busse is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Asthma & Eosinophil. The author has an hindex of 115, co-authored 697 publications receiving 56703 citations. Previous affiliations of William W. Busse include National Institutes of Health & University at Buffalo.

Papers
More filters
Journal ArticleDOI

Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions.

Robert F. Lemanske, +4 more
- 01 Jan 1989 - 
TL;DR: It is found that not only does a RV respiratory tract illness enhance airway reactivity, but it also predisposes the allergic patient to develop LARs, which may be an important factor in virus-induced bronchial hyperresponsiveness.
Journal ArticleDOI

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

Michel Laviolette, +11 more
- 01 Nov 2013 - 
TL;DR: Single-dose intravenous and multiple-dose subcutaneous benralizumab reduced eosinophil counts in airway mucosa/submucosa and sputum and suppressed eosInophils counts in bone marrow and peripheral blood and the safety profile supports further development.
Journal ArticleDOI

Severe exacerbations and decline in lung function in asthma.

Paul M. O'Byrne, +4 more
- 01 Jan 2009 - 
TL;DR: Severe asthma exacerbations are associated with a more rapid decline in lung function and treatment with low doses of inhaled corticosteroid is associated with an attenuation of the decline.
Book

Asthma and Rhinitis

William W. Busse, +1 more
TL;DR: Part 1: Disease Classification Part 2: Epidemiology Part 3: Normal Anatomy, Development and Physiology Part 4: Pathology Part 5: Mast Cells And Basophils Part 6: Eosinophils
Journal Article

Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy

Nicola A. Hanania, +9 more
- 03 May 2011 - 
TL;DR: In this paper, a randomized trial evaluated the efficacy of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) for severe asthma in some patients.